Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program | Zendy

Tinashe Mudzviti | Zendy; Marvelous Sibanda | Zendy; Samuel Gavi | Zendy; Charles C. Maponga | Zendy; Gene D. Morse | Zendy

Open Access

Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program

Author(s) -

Tinashe Mudzviti,

Marvelous Sibanda,

Samuel Gavi,

Charles C. Maponga,

Gene D. Morse

Publication year - 2012

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.1908

Subject(s) - pharmacovigilance , medicine , incidence (geometry) , population , drug , causality (physics) , drug reaction , intensive care medicine , adverse effect , pharmacology , environmental health , physics , quantum mechanics , optics

Cutaneous adverse drug reactions (cADRs) can cause significant morbidity and distress in patients, especially in the HIV-infected population on antiretroviral therapy. Adverse drug reaction monitoring and ascertaining causality in resource-limited settings remain serious challenges. This study was conducted to evaluate causality and measure the incidence of cADRs in HIV-infected patients on highly active antiretroviral therapy. The study was also designed to test a three-step approach in the monitoring and evaluation of ADRs in resource-limited settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research